Therapeutic efficacy of Tofacitinib

1 Rheumatoid Arthritis

The percentages of Tofacitinib-treated patients achieving ACR20, ACR50, and ACR70  responses in Studies RA-I, IV, and V are shown in Table 9. Similar results were observed with  Studies RA-II and III. In trials RA-I through V, patients treated with 5 mg twice daily Tofacitinib  had higher ACR20, ACR50, and ACR70 response rates versus placebo, with or without  background DMARD treatment, at Month 3 and Month 6. Higher ACR20 response rates were  observed within 2 weeks compared to placebo. In the 12-month trials, ACR response rates in Tofacitinib-treated patients were consistent at 6 and 12 months.

from FDA，2024.09